Cargando…

Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program

INTRODUCTION: The availability of the sodium-free potassium binder patiromer opens new opportunities for hyperkalemia management. OBJECTIVE: Our objective was to compare data from a 4-year global pharmacovigilance database of adverse events (AEs) reported in patients prescribed patiromer in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossignol, Patrick, David, Lea, Chan, Christine, Conrad, Ansgar, Weir, Matthew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324724/ https://www.ncbi.nlm.nih.gov/pubmed/34018121 http://dx.doi.org/10.1007/s40801-021-00254-7

Ejemplares similares

Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
por: Esteban‐Fernández, Alberto, et al.
Publicado: (2022)

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors
por: Kloner, Robert A., et al.
Publicado: (2018)

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia
por: Bushinsky, David A, et al.
Publicado: (2015)

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients
por: Kovesdy, Csaba P., et al.
Publicado: (2018)

Pharmacodynamic effects of the K(+) binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats
por: Iyer, Sai Prasad N., et al.
Publicado: (2020)

A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology
por: Rossignol, Patrick
Publicado: (2019)

Gut Microbiota and Host Cometabolism Are Altered by Patiromer-Induced Changes in Serum and Stool Potassium
por: Gao, Bei, et al.
Publicado: (2020)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
por: Lesko, Lawrence J., et al.
Publicado: (2017)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia
por: Colbert, Gates, et al.
Publicado: (2022)

Case report: Patiromer-induced hypercalcemia
por: Wiederkehr, Michael R., et al.
Publicado: (2019)

Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
por: Pinnell, Derek, et al.
Publicado: (2022)

Assessing patiromer utilization and associated serum potassium changes in US veterans with prior sodium polystyrene sulfonate exposure
por: Patel, Shardool, et al.
Publicado: (2023)

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics
por: Weir, Matthew R., et al.
Publicado: (2017)

A Rare Case of Patiromer Induced Hypercalcemia
por: Kanduri, Swetha Rani, et al.
Publicado: (2021)

Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia
por: Li, Lingyun, et al.
Publicado: (2016)

Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a randomized crossover trial
por: Jaques, David A, et al.
Publicado: (2022)

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022)

Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect
por: Bhattarai, Shreeyukta, et al.
Publicado: (2019)

Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
por: Desai, Nihar R., et al.
Publicado: (2019)

Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting
por: Di Palo, Katherine E., et al.
Publicado: (2022)

Diclofenac and the Risk of Rhabdomyolysis: Analysis of Publications and the WHO Global Pharmacovigilance Database
por: Russom, Mulugeta, et al.
Publicado: (2021)

Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database
por: Cicala, Giuseppe, et al.
Publicado: (2023)

Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2022)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease
por: Pitt, Bertram, et al.
Publicado: (2018)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
por: Rosano, Giuseppe M C, et al.
Publicado: (2019)

Largest Experience of Safety and Efficacy of Patiromer in Solid Organ Transplant
por: Schnelle, Kendra, et al.
Publicado: (2020)

An historical overview over Pharmacovigilance
por: Fornasier, Giulia, et al.
Publicado: (2018)

Use of potassium-binder patiromer for up-titration of renin–angiotensin–aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report
por: Jiménez-Marrero, Santiago, et al.
Publicado: (2020)

Potential and Pitfalls of Pharmacovigilance Databases in Oncology
por: Schlam, Ilana, et al.
Publicado: (2023)

Optimizing Therapies in Heart Failure: The Role of Potassium Binders
por: Scicchitano, Pietro, et al.
Publicado: (2022)

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
por: Hoisnard, Léa, et al.
Publicado: (2022)

Evaluation of the Pharmacodynamic Effects of the Potassium Binder RDX7675 in Mice
por: Davidson, James P., et al.
Publicado: (2017)

Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database
por: Ceschi, Alessandro, et al.
Publicado: (2020)

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure
por: Rossignol, Patrick, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
por: Bounthavong, Mark, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5foek5v8ta9pkb8dab4hf6a363